Form 4 for FULC Fulcrum Therapeutics, Inc.
Accepted 2024-07-08 00:00:00 ET · period of report 2024-07-03 · accession 0000950170-24-081949 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-07-08 | 2024-07-03 | FULC | Sapir Alex | See Remarks, Dir | M - OptEx | $3.27 | +150.0K | 193.4K | +346% | +$490.5K |
| D | 2024-07-08 | 2024-07-03 | FULC | Sapir Alex | See Remarks, Dir | M - OptEx | $0.00 | -150.0K | 2.28M | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-03 | M | A | 150,000 | $3.27 | 193,360 | D | — | — | (F1) This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. |
| 2 | Derivative | Stock option - Right to Buy | 2024-07-03 | M | D | 150,000 | $0.00 | 2,280,400 | D | $3.27 · — to 2033-05-11 | 150,000 Common Stock | (F1) This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. (F2) This option was granted on May 12, 2023 and vested 25% on the first anniversary of the vesting commencement date of May 12, 2023. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. |